Dr. Jones on Studying Venetoclax in R/R CLL

Jeffrey Jones, MD, MPH
Published: Friday, Feb 24, 2017



Jeffrey Jones, MD, MPH, assistant professor of Internal Medicine, Division of Hematology, The Ohio State University, discuss the interest in studying venetoclax (Venclexta) in a phase II study for patients with chronic lymphocytic leukemia (CLL).

The interest in venetoclax, according to Jones, was that it is a non-chemotherapeutic option. Retrospective data suggests that older drugs, such as chemotherapy and single-agent monoclonal antibodies, achieve suboptimal responses with overall response rates no higher than 30% in patients progressing after 1 or 2 kinase inhibitors.

Looking for drugs that have a novel mechanism of action and a favorable safety profile is what generated interest in general. Venetoclax has a distinct mechanism of action, a favorable safety profile, and effective single-agent efficacy, which makes it a beneficial option among drugs, Jones states.

SELECTED
LANGUAGE


Jeffrey Jones, MD, MPH, assistant professor of Internal Medicine, Division of Hematology, The Ohio State University, discuss the interest in studying venetoclax (Venclexta) in a phase II study for patients with chronic lymphocytic leukemia (CLL).

The interest in venetoclax, according to Jones, was that it is a non-chemotherapeutic option. Retrospective data suggests that older drugs, such as chemotherapy and single-agent monoclonal antibodies, achieve suboptimal responses with overall response rates no higher than 30% in patients progressing after 1 or 2 kinase inhibitors.

Looking for drugs that have a novel mechanism of action and a favorable safety profile is what generated interest in general. Venetoclax has a distinct mechanism of action, a favorable safety profile, and effective single-agent efficacy, which makes it a beneficial option among drugs, Jones states.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 14th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®Apr 30, 20192.0
Oncology Consultations®: The Advancing Role of CAR T-Cell Therapies in Hematologic MalignanciesApr 30, 20191.5
Publication Bottom Border
Border Publication
x